Pfizer Inc (PFE) 29.64 $PFE
Pfizer Inc. (NYSE: PFE) today issued the following statement:
BusinessWire - Thu Mar 31, 3:29PM CDT
A false press release related to drug pricing and linking to a fake web site was anonymously issued earlier today. It was erroneously attributed to Pfizer and should be disregarded. Pfizer is investigating this matter and evaluating its legal options against the parties responsible. Pfizer is committed to engaging in an honest discussion and real dialogue about the issues that matter to patients.
PFE: 29.64 (-0.43)
Pfizer Tops List of Best Biopharmaceutical Brands
at The Street - Thu Mar 31, 1:09PM CDT
Pfizer scored the top spot in Interbrand Health's inaugural ranking of the top 10 biopharmaceutical brands.
JNJ: 108.20 (-0.78), GILD: 91.86 (-0.11), AZN: 28.16 (-0.16), MRK: 52.91 (-0.31), PFE: 29.64 (-0.43), AMGN: 149.93 (+0.45), GSK: 40.55 (-0.15), NVS: 72.44 (-0.11)
Pfizer: FTC wants more info on planned Allergan acquisition
By The Associated Press - AP - Wed Mar 30, 2:04PM CDT
NEW YORK (AP) — Pfizer says the U.S. Federal Trade Commission has requested more information about its planned acquisition of rival drugmaker Allergan in a deal aimed at reducing Pfizer's tax bill.
AGN: 268.03 (-6.91), PFE: 29.64 (-0.43)
Pfizer and Allergan Receive Request for Additional Information from Federal Trade Commission Regarding Proposed Combination
BusinessWire - Wed Mar 30, 11:41AM CDT
--Pfizer and Allergan continue to expect the transaction to close in the second half of 2016
AGN: 268.03 (-6.91), PFE: 29.64 (-0.43)
Bristol-Myers Squibb and Pfizer Announce Global Real-World Data Program and Present New Analyses of Eliquis (apixaban) at the American College of Cardiology's 65th Annual Scientific Session
BusinessWire - Wed Mar 30, 6:45AM CDT
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced today that 17 abstracts will be presented at the American College of Cardiology's 65th Annual Scientific Session (ACC.16), to be held April 2-4 in Chicago, IL. The new analyses contribute to the Bristol-Myers Squibb and Pfizer Alliance's body of evidence on the use of Eliquis to reduce the risk of stroke in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of patients with venous thromboembolism (VTE). Abstracts include new analyses from Phase 3 ARISTOTLE and AMPLIFY clinical studies, as well as a number of retrospective analyses of real-world data. "The Alliance is pleased to present new analyses from both Phase 3 clinical trials and real-world databases at this important cardiology conference," said Douglas Manion, M.D., head of specialty development, Bristol-Myers Squibb. "Clinical trial data help to evaluate the safety and efficacy of Eliquis under well-controlled circumstances, while real-world data can offer additional insight into the use of Eliquis for its approved indications in routine clinical practice."
PFE: 29.64 (-0.43), BMY: 63.88 (+0.44)
Jim Cramer's 'Mad Money' Recap: Why You Need Technical Analysis
at The Street - Tue Mar 29, 6:00PM CDT
Why study charts? Because charts are like the footprints at the scene of the crime, clues to what the big money managers are likely thinking, Cramer says.
MNST: 133.38 (-1.52), T: 39.17 (-0.20), AA: 9.58 (-0.10), PFE: 29.64 (-0.43), DPZ: 131.86 (+0.89), LVS: 51.68 (-0.55), AAPL: 108.99 (-0.57)
What Happens to U.S. Companies If Trump or Sanders Roll Back Free Trade?
at The Street - Tue Mar 29, 9:30AM CDT
Free trade has fostered massive global production networks. Trump and Sanders are pushing policies that could disrupt those networks. Then what?
GE: 31.79 (-0.04), PFE: 29.64 (-0.43), AAPL: 108.99 (-0.57)
Peripheral Neuropathy (Sensory) Market Pipeline Global Review H2 2015
PR Newswire - Mon Mar 28, 1:00PM CDT
New market research titled "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2015" provides an overview of the Peripheral Neuropathy's therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
PFE: 29.64 (-0.43)
AstraZeneca or AbbVie: Which Is Better for Dividend Growth Investors?
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 28, 7:21AM CDT
SOURCE: FLICKR USER PICTURES OF MONEY. Dividend-paying companies have been shown to outperform their non-dividend-paying counterparts, so it's little surprise that more investors are focusing on dividend investment strategies. One strategy that's...
PFE: 29.64 (-0.43), AZN: 28.16 (-0.16), ABBV: 57.12 (+0.12)
Krispy Is Kremed; RIP Andy Grove; Biotechs in No-Man's Land: Jim Cramer's Best Blogs
at The Street - Fri Mar 25, 8:00PM CDT
Cramer dissects Krispy Kreme, honors a tech pioneer and laments the state of biotech stocks.
BIIB: 260.32 (+6.14), VRX: 26.30 (-0.77), WMT: 68.49 (-0.31), INTC: 32.35 (-0.36), SHLD: 15.31 (+0.19), AGN: 268.03 (-6.91), SBUX: 59.70 (-0.31), JACK: 63.87 (-0.59), JNJ: 108.20 (-0.78), DNKN: 47.17 (+0.19), IBM: 151.45 (+3.04), CMG: 470.97 (+4.82), ABBV: 57.12 (+0.12), SNY: 40.16 (-0.53), KKD: 15.59 (+0.16), REGN: 360.44 (+0.76), HD: 133.43 (+0.01), PFE: 29.64 (-0.43), LLY: 72.01 (+0.23), GSK: 40.55 (-0.15), BMY: 63.88 (+0.44), PLKI: 52.06 (+0.28), DIN: 93.43 (-0.91), CELG: 100.09 (+1.29), QSR: 38.83 (-0.50), GILD: 91.86 (-0.11), MRK: 52.91 (-0.31), AZN: 28.16 (-0.16), MCD: 125.68 (-0.15), WEN: 10.89 (+0.03)
10 Women Who Would Be a Great Addition to Any Company's Board
at The Street - Thu Mar 24, 12:03PM CDT
Seven companies in the S&P 500 have no women on their boards. Maybe they're having trouble finding the right women? We aren't. Here are 10 that would make great additions.
CXO: 101.04 (-0.91), HST: 16.70 (+0.24), MDLZ: 40.12 (-0.34), HON: 112.05 (-0.12), CAH: 81.95 (+0.17), KORS: 56.96 (+0.09), IDA: 74.59 (-0.06), DO: 21.73 (+0.35), AMAT: 21.18 (+0.14), EOG: 72.58 (-1.08), MSFT: 55.23 (+0.18), REV: 36.41 (+0.53), MU: 10.47 (-0.01), HAR: 89.04 (+2.03), SWKS: 77.90 (+0.05), PFE: 29.64 (-0.43), MCHP: 48.20 (-0.64), LLTC: 44.56 (-0.22), UL: 45.18 (-0.59), MGM: 21.44 (+0.15), CELG: 100.09 (+1.29), GILD: 91.86 (-0.11), TXN: 57.42 (-0.95), MRK: 52.91 (-0.31), QLGC: 13.44 (+0.06), ADI: 59.19 (+0.08), MRO: 11.14 (+0.61), CVX: 95.40 (+0.15), XRAY: 61.63 (-0.43), NVS: 72.44 (-0.11), GRMN: 39.96 (+0.10), CCE: 50.74 (-0.35), K: 76.55 (-0.28), JNPR: 25.51 (unch), IBM: 151.45 (+3.04), APA: 48.81 (+0.17), GOOGL: 762.90 (-5.44), TER: 21.59 (+0.03), ALGN: 72.69 (+0.68), MET: 43.94 (-0.79), DISCA: 28.63 (+0.54), FCAU: 8.06 (-0.09), ISIL: 13.37 (+0.02), ORCL: 40.91 (-0.06), SQ: 15.28 (+0.26), GS: 156.98 (+0.48), QRVO: 50.41 (-0.82), LRCX: 82.60 (+0.41), BAX: 41.08 (-0.18), GM: 31.43 (+0.44), CRUS: 36.41 (+0.08), PG: 82.31 (-0.37), AVGO: 154.50 (-2.43), GSBD: 19.60 (+0.07), CRM: 73.83 (-0.47)
The 3 Best Stocks to Own in Retirement
Todd Campbell, Sean Williams, and Steve Symington, The Motley Fool - Motley Fool - Thu Mar 24, 10:03AM CDT
Image source: Pixabay. Retirees are living longer than ever before, and that means retirees are focusing their portfolios less on slow-growth Treasury bonds and more on stocks so they don't outlive their savings. While stocks can add some punch to...
PFE: 29.64 (-0.43), VZ: 54.08 (+0.04), AFL: 63.14 (-0.59)
Pfizer's Revised Filing for Xeljanz Accepted for Review in EU
Zacks Equity Research - Zacks Investment Research - Thu Mar 24, 9:20AM CDT
Pfizer (PFE) had resubmitted the Marketing Authorization Application (MAA) for Xeljanz, which was accepted for review by the European Medicines Agency.
EBS: 36.35 (+1.13), PFE: 29.64 (-0.43), AMAG: 23.40 (+1.28), ANIK: 44.72 (-0.26)
If It Wasn't For Pfizer, Allergan Investors Might Be Getting Pummeled
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 24, 8:21AM CDT
SOURCE: FLICKR USER STOCKMONKEYS.COM The unraveling of its buy-reprice-relaunch strategy has led to shares in Valeant Pharmaceuticals crumbling 80% in the past year, but Valeant Pharmaceuticals is far from the only publicly traded biopharma...
AGN: 268.03 (-6.91), VRX: 26.30 (-0.77), PFE: 29.64 (-0.43), HZNP: 16.57 (+0.56), TEVA: 53.51 (-0.89), DEPO: 13.93 (+0.04)
Portola Pharmaceuticals' Betrixaban Misses Mark, But All Is Not Lost
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 24, 8:14AM CDT
SOURCE: PORTOLA PHARMACEUTICALS Portola Pharmaceuticals ' 7,513 person head to head study evaluating its next-generation anticoagulant betrixaban against standard of care Lovenox in the prevention of blood clots missed its endpoint in one trial...
JNJ: 108.20 (-0.78), PTLA: 20.40 (+0.20), PFE: 29.64 (-0.43), BMY: 63.88 (+0.44), SNY: 40.16 (-0.53)
Allergan Is a Good Buy for Investors, With or Without Pfizer
at The Street - Thu Mar 24, 7:38AM CDT
The Irish pharmaceutical company is launching a blockbuster drug, and its share price seems primed for a rebound.
AGN: 268.03 (-6.91), PFE: 29.64 (-0.43)
Pfizer Announces European Medicines Agency Accepted for Review Its Marketing Authorization Application for XELJANZ(R) (Tofacitinib Citrate) for the Treatment of Moderate to Severe Rheumatoid Arthritis
BusinessWire - Wed Mar 23, 3:15PM CDT
Pfizer Inc. (NYSE
FE) announced today that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for XELJANZ(R) (tofacitinib citrate) 5 mg tablets twice daily for the treatment of patients with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX). The EMA will now initiate its review of the XELJANZ MAA.
PFE: 29.64 (-0.43)
Follicular Thyroid Cancer - Pipeline Review, H1 2016 Featuring Exelixis, Inc., Genzyme Corporation, Novartis AG & Pfizer Inc. - Research and Markets
BusinessWire - Wed Mar 23, 1:09PM CDT
Research and Markets (http://www.researchandmarkets.com/research/3v53qr/follicular) has announced the addition of the "Follicular Thyroid Cancer - Pipeline Review, H1 2016" report to their offering.
PFE: 29.64 (-0.43), NVS: 72.44 (-0.11), EXEL: 4.00 (+0.10)
Novartis Stock Downgraded: 3 Things You Need to Know
Rich Smith, The Motley Fool - Motley Fool - Wed Mar 23, 12:00PM CDT
With its stock down 26% in 52 weeks, German pharmaceutical giant Novartis is looking cheap and winning fans on Wall Street. But Leerink Partners is not one of them. According to data from S&P Global Market Intelligence , 16 out of 34...
JNJ: 108.20 (-0.78), PFE: 29.64 (-0.43), NVS: 72.44 (-0.11)
Stocks Run in Place as Brussels Attack Paralyzes Wall Street
at The Street - Tue Mar 22, 3:09PM CDT
A quieter holiday trading week was disrupted by tragedy on Tuesday, with dual explosions at a Brussels airport and metro station reigniting global concerns about terrorism.
VRX: 26.30 (-0.77), DAL: 48.68 (-0.65), PFE: 29.64 (-0.43), DB: 16.94 (-0.18), LL: 13.12 (+0.21), PCLN: 1,288.96 (-28.07), CELG: 100.09 (+1.29), UAL: 59.86 (+0.04), LUV: 44.80 (-0.18), GILD: 91.86 (-0.11), EXPE: 107.82 (+0.02), AAL: 41.01 (-0.37), AAPL: 108.99 (-0.57), IHG: 41.27 (+0.98)
Pfizer Inc. (NYSE: PFE) today issued the following statement:
BusinessWire - Thu Mar 31, 3:29PM CDT
A false press release related to drug pricing and linking to a fake web site was anonymously issued earlier today. It was erroneously attributed to Pfizer and should be disregarded. Pfizer is investigating this matter and evaluating its legal options against the parties responsible. Pfizer is committed to engaging in an honest discussion and real dialogue about the issues that matter to patients.
PFE: 29.64 (-0.43)
Pfizer Tops List of Best Biopharmaceutical Brands
at The Street - Thu Mar 31, 1:09PM CDT
Pfizer scored the top spot in Interbrand Health's inaugural ranking of the top 10 biopharmaceutical brands.
JNJ: 108.20 (-0.78), GILD: 91.86 (-0.11), AZN: 28.16 (-0.16), MRK: 52.91 (-0.31), PFE: 29.64 (-0.43), AMGN: 149.93 (+0.45), GSK: 40.55 (-0.15), NVS: 72.44 (-0.11)
Pfizer: FTC wants more info on planned Allergan acquisition
By The Associated Press - AP - Wed Mar 30, 2:04PM CDT
NEW YORK (AP) — Pfizer says the U.S. Federal Trade Commission has requested more information about its planned acquisition of rival drugmaker Allergan in a deal aimed at reducing Pfizer's tax bill.
AGN: 268.03 (-6.91), PFE: 29.64 (-0.43)
Pfizer and Allergan Receive Request for Additional Information from Federal Trade Commission Regarding Proposed Combination
BusinessWire - Wed Mar 30, 11:41AM CDT
--Pfizer and Allergan continue to expect the transaction to close in the second half of 2016
AGN: 268.03 (-6.91), PFE: 29.64 (-0.43)
Bristol-Myers Squibb and Pfizer Announce Global Real-World Data Program and Present New Analyses of Eliquis (apixaban) at the American College of Cardiology's 65th Annual Scientific Session
BusinessWire - Wed Mar 30, 6:45AM CDT
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced today that 17 abstracts will be presented at the American College of Cardiology's 65th Annual Scientific Session (ACC.16), to be held April 2-4 in Chicago, IL. The new analyses contribute to the Bristol-Myers Squibb and Pfizer Alliance's body of evidence on the use of Eliquis to reduce the risk of stroke in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of patients with venous thromboembolism (VTE). Abstracts include new analyses from Phase 3 ARISTOTLE and AMPLIFY clinical studies, as well as a number of retrospective analyses of real-world data. "The Alliance is pleased to present new analyses from both Phase 3 clinical trials and real-world databases at this important cardiology conference," said Douglas Manion, M.D., head of specialty development, Bristol-Myers Squibb. "Clinical trial data help to evaluate the safety and efficacy of Eliquis under well-controlled circumstances, while real-world data can offer additional insight into the use of Eliquis for its approved indications in routine clinical practice."
PFE: 29.64 (-0.43), BMY: 63.88 (+0.44)
Jim Cramer's 'Mad Money' Recap: Why You Need Technical Analysis
at The Street - Tue Mar 29, 6:00PM CDT
Why study charts? Because charts are like the footprints at the scene of the crime, clues to what the big money managers are likely thinking, Cramer says.
MNST: 133.38 (-1.52), T: 39.17 (-0.20), AA: 9.58 (-0.10), PFE: 29.64 (-0.43), DPZ: 131.86 (+0.89), LVS: 51.68 (-0.55), AAPL: 108.99 (-0.57)
What Happens to U.S. Companies If Trump or Sanders Roll Back Free Trade?
at The Street - Tue Mar 29, 9:30AM CDT
Free trade has fostered massive global production networks. Trump and Sanders are pushing policies that could disrupt those networks. Then what?
GE: 31.79 (-0.04), PFE: 29.64 (-0.43), AAPL: 108.99 (-0.57)
Peripheral Neuropathy (Sensory) Market Pipeline Global Review H2 2015
PR Newswire - Mon Mar 28, 1:00PM CDT
New market research titled "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2015" provides an overview of the Peripheral Neuropathy's therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
PFE: 29.64 (-0.43)
AstraZeneca or AbbVie: Which Is Better for Dividend Growth Investors?
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 28, 7:21AM CDT
SOURCE: FLICKR USER PICTURES OF MONEY. Dividend-paying companies have been shown to outperform their non-dividend-paying counterparts, so it's little surprise that more investors are focusing on dividend investment strategies. One strategy that's...
PFE: 29.64 (-0.43), AZN: 28.16 (-0.16), ABBV: 57.12 (+0.12)
Krispy Is Kremed; RIP Andy Grove; Biotechs in No-Man's Land: Jim Cramer's Best Blogs
at The Street - Fri Mar 25, 8:00PM CDT
Cramer dissects Krispy Kreme, honors a tech pioneer and laments the state of biotech stocks.
BIIB: 260.32 (+6.14), VRX: 26.30 (-0.77), WMT: 68.49 (-0.31), INTC: 32.35 (-0.36), SHLD: 15.31 (+0.19), AGN: 268.03 (-6.91), SBUX: 59.70 (-0.31), JACK: 63.87 (-0.59), JNJ: 108.20 (-0.78), DNKN: 47.17 (+0.19), IBM: 151.45 (+3.04), CMG: 470.97 (+4.82), ABBV: 57.12 (+0.12), SNY: 40.16 (-0.53), KKD: 15.59 (+0.16), REGN: 360.44 (+0.76), HD: 133.43 (+0.01), PFE: 29.64 (-0.43), LLY: 72.01 (+0.23), GSK: 40.55 (-0.15), BMY: 63.88 (+0.44), PLKI: 52.06 (+0.28), DIN: 93.43 (-0.91), CELG: 100.09 (+1.29), QSR: 38.83 (-0.50), GILD: 91.86 (-0.11), MRK: 52.91 (-0.31), AZN: 28.16 (-0.16), MCD: 125.68 (-0.15), WEN: 10.89 (+0.03)
10 Women Who Would Be a Great Addition to Any Company's Board
at The Street - Thu Mar 24, 12:03PM CDT
Seven companies in the S&P 500 have no women on their boards. Maybe they're having trouble finding the right women? We aren't. Here are 10 that would make great additions.
CXO: 101.04 (-0.91), HST: 16.70 (+0.24), MDLZ: 40.12 (-0.34), HON: 112.05 (-0.12), CAH: 81.95 (+0.17), KORS: 56.96 (+0.09), IDA: 74.59 (-0.06), DO: 21.73 (+0.35), AMAT: 21.18 (+0.14), EOG: 72.58 (-1.08), MSFT: 55.23 (+0.18), REV: 36.41 (+0.53), MU: 10.47 (-0.01), HAR: 89.04 (+2.03), SWKS: 77.90 (+0.05), PFE: 29.64 (-0.43), MCHP: 48.20 (-0.64), LLTC: 44.56 (-0.22), UL: 45.18 (-0.59), MGM: 21.44 (+0.15), CELG: 100.09 (+1.29), GILD: 91.86 (-0.11), TXN: 57.42 (-0.95), MRK: 52.91 (-0.31), QLGC: 13.44 (+0.06), ADI: 59.19 (+0.08), MRO: 11.14 (+0.61), CVX: 95.40 (+0.15), XRAY: 61.63 (-0.43), NVS: 72.44 (-0.11), GRMN: 39.96 (+0.10), CCE: 50.74 (-0.35), K: 76.55 (-0.28), JNPR: 25.51 (unch), IBM: 151.45 (+3.04), APA: 48.81 (+0.17), GOOGL: 762.90 (-5.44), TER: 21.59 (+0.03), ALGN: 72.69 (+0.68), MET: 43.94 (-0.79), DISCA: 28.63 (+0.54), FCAU: 8.06 (-0.09), ISIL: 13.37 (+0.02), ORCL: 40.91 (-0.06), SQ: 15.28 (+0.26), GS: 156.98 (+0.48), QRVO: 50.41 (-0.82), LRCX: 82.60 (+0.41), BAX: 41.08 (-0.18), GM: 31.43 (+0.44), CRUS: 36.41 (+0.08), PG: 82.31 (-0.37), AVGO: 154.50 (-2.43), GSBD: 19.60 (+0.07), CRM: 73.83 (-0.47)
The 3 Best Stocks to Own in Retirement
Todd Campbell, Sean Williams, and Steve Symington, The Motley Fool - Motley Fool - Thu Mar 24, 10:03AM CDT
Image source: Pixabay. Retirees are living longer than ever before, and that means retirees are focusing their portfolios less on slow-growth Treasury bonds and more on stocks so they don't outlive their savings. While stocks can add some punch to...
PFE: 29.64 (-0.43), VZ: 54.08 (+0.04), AFL: 63.14 (-0.59)
Pfizer's Revised Filing for Xeljanz Accepted for Review in EU
Zacks Equity Research - Zacks Investment Research - Thu Mar 24, 9:20AM CDT
Pfizer (PFE) had resubmitted the Marketing Authorization Application (MAA) for Xeljanz, which was accepted for review by the European Medicines Agency.
EBS: 36.35 (+1.13), PFE: 29.64 (-0.43), AMAG: 23.40 (+1.28), ANIK: 44.72 (-0.26)
If It Wasn't For Pfizer, Allergan Investors Might Be Getting Pummeled
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 24, 8:21AM CDT
SOURCE: FLICKR USER STOCKMONKEYS.COM The unraveling of its buy-reprice-relaunch strategy has led to shares in Valeant Pharmaceuticals crumbling 80% in the past year, but Valeant Pharmaceuticals is far from the only publicly traded biopharma...
AGN: 268.03 (-6.91), VRX: 26.30 (-0.77), PFE: 29.64 (-0.43), HZNP: 16.57 (+0.56), TEVA: 53.51 (-0.89), DEPO: 13.93 (+0.04)
Portola Pharmaceuticals' Betrixaban Misses Mark, But All Is Not Lost
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 24, 8:14AM CDT
SOURCE: PORTOLA PHARMACEUTICALS Portola Pharmaceuticals ' 7,513 person head to head study evaluating its next-generation anticoagulant betrixaban against standard of care Lovenox in the prevention of blood clots missed its endpoint in one trial...
JNJ: 108.20 (-0.78), PTLA: 20.40 (+0.20), PFE: 29.64 (-0.43), BMY: 63.88 (+0.44), SNY: 40.16 (-0.53)
Allergan Is a Good Buy for Investors, With or Without Pfizer
at The Street - Thu Mar 24, 7:38AM CDT
The Irish pharmaceutical company is launching a blockbuster drug, and its share price seems primed for a rebound.
AGN: 268.03 (-6.91), PFE: 29.64 (-0.43)
Pfizer Announces European Medicines Agency Accepted for Review Its Marketing Authorization Application for XELJANZ(R) (Tofacitinib Citrate) for the Treatment of Moderate to Severe Rheumatoid Arthritis
BusinessWire - Wed Mar 23, 3:15PM CDT
Pfizer Inc. (NYSE
FE) announced today that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for XELJANZ(R) (tofacitinib citrate) 5 mg tablets twice daily for the treatment of patients with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX). The EMA will now initiate its review of the XELJANZ MAA. PFE: 29.64 (-0.43)
Follicular Thyroid Cancer - Pipeline Review, H1 2016 Featuring Exelixis, Inc., Genzyme Corporation, Novartis AG & Pfizer Inc. - Research and Markets
BusinessWire - Wed Mar 23, 1:09PM CDT
Research and Markets (http://www.researchandmarkets.com/research/3v53qr/follicular) has announced the addition of the "Follicular Thyroid Cancer - Pipeline Review, H1 2016" report to their offering.
PFE: 29.64 (-0.43), NVS: 72.44 (-0.11), EXEL: 4.00 (+0.10)
Novartis Stock Downgraded: 3 Things You Need to Know
Rich Smith, The Motley Fool - Motley Fool - Wed Mar 23, 12:00PM CDT
With its stock down 26% in 52 weeks, German pharmaceutical giant Novartis is looking cheap and winning fans on Wall Street. But Leerink Partners is not one of them. According to data from S&P Global Market Intelligence , 16 out of 34...
JNJ: 108.20 (-0.78), PFE: 29.64 (-0.43), NVS: 72.44 (-0.11)
Stocks Run in Place as Brussels Attack Paralyzes Wall Street
at The Street - Tue Mar 22, 3:09PM CDT
A quieter holiday trading week was disrupted by tragedy on Tuesday, with dual explosions at a Brussels airport and metro station reigniting global concerns about terrorism.
VRX: 26.30 (-0.77), DAL: 48.68 (-0.65), PFE: 29.64 (-0.43), DB: 16.94 (-0.18), LL: 13.12 (+0.21), PCLN: 1,288.96 (-28.07), CELG: 100.09 (+1.29), UAL: 59.86 (+0.04), LUV: 44.80 (-0.18), GILD: 91.86 (-0.11), EXPE: 107.82 (+0.02), AAL: 41.01 (-0.37), AAPL: 108.99 (-0.57), IHG: 41.27 (+0.98)
